



ASX ANNOUNCEMENT

25 JUNE 2019

NOTICE GIVEN UNDER SECTION 708A(5)(e) OF CORPORATIONS ACT

Cann Group Limited (**Cann**) (ASX: CAN) gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

- (a) Cann has on 25 June 2019 issued 1,000,000 fully paid ordinary shares as a result of a holder of Underwriting Options exercising those options, without disclosure to the investor under Part 6D.2 of the *Corporations Act*; and
- (b) as at the date of this notice:
 - (1) Cann has complied with the provisions of Chapter 2M of the *Corporations Act* as they apply to Cann;
 - (2) Cann has complied with section 674 of the *Corporations Act*; and
 - (3) there is no information that is “excluded information” within the meaning of sections 708A(7) and 708A(8) of the *Corporations Act* that is required to be set out in this notice under section 708A(6)(e) of the *Corporations Act*.

Signed for and on behalf of Cann Group Limited.

Richard Baker
Company Secretary

For further information please contact:

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 498 000 762
clive.fanning@canngrouponlimited.com

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada's largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.9% shareholding.